Marco Meglio

The chief medical officer of Cortexyme discussed the company’s investigational agent atuzaginstat, its mechanism of action, and the findings of the phase 2/3 GAIN trial.

The model discovered nonsequential, overlapping disease progression trajectories, supporting the use of nondeterministic disease progression models.

Aquestive does not anticipate a need for any additional studies and is preparing for the commercial launch of Libervant in the first half of 2022, if approved.

Of those who reported new or worsening neurological symptoms, 77.8% didn’t require any additional medication to treat their symptoms.

Higher percentages of infants were event-free and were classified as having a motor-milestone response at month 12 than in historical cohorts.

The label now includes the use of ultrasound as a muscle localization technique in adults with spasticity, and includes muscles of the elbow, forearm, hand, and thumb.

The ICARE AD-US trial is expected to enroll 6000 participants, with at least 16% of the population aimed at including those from underrepresented communities. The unrelated confirmatory phase 4 trial is still in the process of being designed.

The effect of methylphenidate on Alzheimer disease apathy was observed at 2 months and was sustained throughout the 6 months of the study.

Patients with neurological sequelae from COVID-19 were significantly more likely to die before discharge (22.2%) compared with non-neuro-COVID patients (14.4%).

The assistant professor of neurology at Harvard Medical School detailed his recent review involving the diagnosis and management of posttraumatic headache with associated cranial neuralgias.

Complete resolution of the index T2-lesion and resolution of all T2 lesions occurred most often in patients with MOGAD rather than AQP4-IgG-NMOSD or MS.

The therapy, already FDA-approved for individuals with pulmonary artery disease, was significantly associated with reduced likelihood of Alzheimer disease in both the 65-74 year range and those older than 75 years.

The agent, which is FDA-approved for hyperlipidemia, showed significant improvements in plasma glucose, lipid levels, and trends in cardiovascular imaging biomarkers.

Many applicants referenced an early interest and exposure to neurology, often describing their first courses in neurology sparking their desire to learn more about how the brain works.

Investigators observed declines in delayed verbal recall in 20% to 30% of individuals who underwent a dominant temporal lobe resection for treatment of epilepsy.

Basis for the approval was the SENZA-PDN randomized controlled trial, which showed the system’s ability to substantially sustain pain relief and improve health-related quality of life.

Treatment retention with cenobamate ranged from 73% of patients at 1 year to 59% of patients at 6 years.

The majority of tests with the tool correlated with Expanded Disability Status Scale scores, 29-item Multiple Sclerosis Impact Scale items or subscales scores, and/or normalized brain volume measures.

The duo from Cleveland Clinic stressed the reasons for conducting real-world data assessing migraine treatments and why it can lead to the ultimate goal of treatment optimization.

The data also indicated that ticagrelor plus aspirin treatment prevents disabling stroke in the subgroups of patients presenting with minor and with moderate stroke.

Instead of a smooth-contoured, thin, and regular ring or arc typically seen, pattern 3 patients had atypical rings such as irregularly thick rings and arcs.

The effect observed in on ALSFRS-R at week 48 and progression-free survival further support the premise of greater treatment effect when masitinib is initiated earlier in the disease.

Orelabrutinib has the potential to inhibit B cell and myeloid cell effector functions in the central nervous system and may provide a clinically meaningful benefit on progression in all forms of MS.

Use of prescription preventive medication was reported by less than 10% of participants throughout 3 years of follow-up after the completion of the CHAMP trial.

These study results highlight the interest in immunosuppressive therapy taken before or during pregnancy and to reduce the risk of relapse during pregnancy and 1 year postpartum.

The position statement considers the diagnosis of dementia, problems in decision making, symptoms and behavioral management, and the relationship between dementia care and society.

A significant proportion of survivors from ICH required substantial continuing care sector resources, namely complex continuing care, long-term care, rehabilitation services, and home care.

Invalid and valid performers did not differ regarding demographic, patient-reported, and disease-related outcomes.

The chief medical officer of Scholar Rock described how the investigational apitegromab aims to fill some of the current unmet needs for patients with spinal muscular atrophy.

Serum GFAP levels showed consistent correlations with disease activity and the largest area under the ROC curve to differentiate attacks from remissions in individuals with NMOSD.